Advances in treatment of lung cancer with targeted therapy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Archives of Pathology & Laboratory Medicine

• Publication date

  2012-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.5858/arpa.2011-0618-RAPMID 22540298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2011cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.

  2010cited by this paper
• Targeted cancer therapies

  2010cited by this paper
• Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers.

  2009cited by this paper
• Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

  2009cited by this paper
• Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

  2009cited by this paper
• Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer.

  2009cited by this paper
• Clinical significance of TTF‐1 protein expression and TTF‐1 gene amplification in lung adenocarcinoma

  2009cited by this paper
• Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer

  2009cited by this paper
• MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Lung cancer trials probe effects of maintenance therapy, targeted agents.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2008cited by this paper
• Expression and mutational analysis of MET in human solid cancers

  2008cited by this paper
• Drug development of MET inhibitors: targeting oncogene addiction and expedience

  2008cited by this paper
• Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis

  2008cited by this paper
• EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

  2008cited by this paper
• Lung cancer.

  2008cited by this paper
• Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

  2008cited by this paper
• A mouse model for EML4-ALK-positive lung cancer

  2008cited by this paper
• A Translational View of the Molecular Pathogenesis of Lung Cancer

  2007cited by this paper
• Prognostic significance of a histologic subtype in small adenocarcinoma of the lung: the impact of nonbronchioloalveolar carcinoma components.

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

  2007cited by this paper
• MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer.

  2007cited by this paper
• WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

  2007cited by this paper
• EGFR and erbB2 mutation status in Japanese lung cancer patients

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

  2006cited by this paper
• Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer

  2006cited by this paper
• Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.

  2006cited by this paper
• Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma

  2006cited by this paper
• Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

  2005cited by this paper
• Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

  2005cited by this paper
• Bronchioloalveolar carcinoma: A Review of the Epidemiology, Pathology, and Treatment

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004influential reference
• Athletics: Momentous sprint at the 2156 Olympics?

  2004cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Pathology and genetics of tumours of the lung , pleura, thymus and heart

  2004cited by this paper
• Trastuzumab for the Treatment of Non—Small-Cell Lung Cancer

  2003cited by this paper
• World Health Organization Classification of Tumours

  2002cited by this paper
• Clinical impact of novel treatment strategies

  2002cited by this paper
• Trastuzumab in the treatment of non-small cell lung cancer.

  2002cited by this paper
• Papillary Renal Cell Carcinoma: Analysis of Germline Mutations in the MET Proto-Oncogene in a Clinic-Based Population

  2001cited by this paper
• High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining.

  1996cited by this paper
• Small adenocarcinoma of the lung. Histologic characteristics and prognosis

  1995cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

  1994cited by this paper
• Chromosome abnormalities in human non-small cell lung cancer.

  1992cited by this paper
• Lung cancer.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• Open access, freely available online Correspondence Misleading Information on the Properties of Vitamin C

  year unknowncited by this paper

• Stereotactic radiosurgery for lung cancer spinal metastases

  2025cites this paper
• Survival days of patients with metastatic spinal tumors of lung cancer requiring surgery: a prospective multicenter study

  2025cites this paper
• KRAS mutants confer platinum resistance by regulating ALKBH5 posttranslational modifications in lung cancer

  2025cites this paper
• Prediction of lung adenocarcinoma prognosis and clinical treatment efficacy by telomere-associated gene risk model

  2025cites this paper
• Impact of smoking on the effectiveness of different non-small-cell lung cancer therapies

  2025cites this paper
• Screening on Lung Cancer: Etiology, Pathophysiology, Treatment

  2025cites this paper
• ACADL-YAP axis activity in non-small cell lung cancer carcinogenicity

  2024cites this paper
• Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR)

  2024cites this paper
• Case report: A case of Savolitinib in the treatment of MET amplification mutation advanced lung adenocarcinoma with rare bilateral breast metastasis

  2024cites this paper
• PI3Kα inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells.

  2024cites this paper
• Costs of traditional Chinese medicine treatment for inpatients with lung cancer in China: a national study

  2023cites this paper
• Recurrent lung adenocarcinoma benefits from microwave ablation following multidisciplinary treatments: A case with long-term survival

  2023cites this paper
• Progress in genome-inspired treatment decisions for multifocal lung adenocarcinoma

  2023cites this paper
• Clinical outcomes following total en bloc spondylectomy for spinal metastases from lung cancer.

  2023cites this paper
• USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway

  2023cites this paper
• Preoperative prediction of vasculogenic mimicry in lung adenocarcinoma using a CT radiomics model.

  2023cites this paper
• Anticancer activities of sewewanua leaf extracts (Clerodendrum fragrans (Vent.) Wild) againts A549 lung cancer cell

  2022cites this paper
• Mutation patterns of epidermal growth factor receptor gene in non-small cell lung cancer among Egyptian patients

  2022cites this paper
• MALAT-1 Expression Correlates with Prognosis in Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis

  2021cites this paper
• The Diagnostic value of TTF-1 and P63 Immunostaining in the Classification of Non Small cell Lung Carcinoma

  2021cites this paper
• SMOKING CARCINOGENS AND LUNG CANCER – A REVIEW

  2021cites this paper
• Cyclin H Regulates Lung Cancer Progression as a Carcinoma Inducer

  2021cites this paper
• Anticancer Activities of Sesewanua Leaf Extracts (Clerodendrum fragrans (Vent.) Willd) Against A549 Lung Cancer Cell

  2021cites this paper
• Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development

  2020cites this paper
• Lower Respiratory Tract

  2020cites this paper
• Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital

  2019cites this paper
• IHC–The need of the hour in classifying lung tumours effectively on guided biopsies!

  2019cites this paper
• Prognostic factors in patients with metastatic spine tumors derived from lung cancer—a novel scoring system for predicting life expectancy

  2018cites this paper
• Statistical assessment of repeated measures data with application in oncology

  2017cites this paper
• Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

  2017cites this paper
• Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.

  2017cites this paper
• Treatment Outcome of Metastatic Spine Tumor in Lung Cancer Patients

  2017cites this paper
• [Omics technologies in diagnostics of lung adenocarcinoma].

  2017cites this paper
• Next-Generation Sequencing for Drug Designing and Development: An Omics Approach for Cancer Treatment

  2017cites this paper
• Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma

  2017cites this paper
• Aurora B expression modulates paclitaxel response in non-small cell lung cancer

  2017cites this paper
• Omics technologies in diagnosis of lung adenocarcinoma

  2017cites this paper
• Combined analysis identifies six genes correlated with augmented malignancy from non-small cell to small cell lung cancer

  2016cites this paper
• A validated preoperative score predicting survival and functional outcome in lung cancer patients operated with posterior decompression and stabilization for metastatic spinal cord compression

  2016cites this paper
• Overexpression of the non-coding SOX2OT variants 4 and 7 in lung tumors suggests an oncogenic role in lung cancer

  2016cites this paper
• EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.

  2016cites this paper
• Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer

  2016cites this paper
• Utility of folate receptor alpha immunohistochemistry in cytology specimens of metastatic breast carcinoma, metastatic serous carcinoma of Müllerian origin, and primary lung adenocarcinoma

  2016cites this paper
• Anti-ABCG2 scFv antibody of lung adenocarcinoma increases chemosensitivity and induces apoptosis through the activation of mitochondrial pathway.

  2016cites this paper
• Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer

  2016cites this paper
• Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study.

  2016cites this paper
• Screening Les tests génétiques des maladies respiratoires : sommes-nous rendus là ?

  2016cites this paper
• Aurora B expression modulates paclitaxel response in non-small cell lung cancer 1 2

  2016cites this paper
• Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer

  2015cites this paper
• Posterior decompression and spine stabilization for metastatic spinal cord compression in the cervical spine. A matched pair analysis.

  2015cites this paper
• Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study.

  2015cites this paper
• NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway

  2015cites this paper
• Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer

  2015cites this paper
• Loss of β-arrestin1 expression predicts unfavorable prognosis for non-small cell lung cancer patients

  2015cites this paper
• Prognostic Clinico-Pathological Features of 99 Cases Advanced Non-Small Cell Lung Cancer—Egyptian National Cancer Institute

  2015cites this paper
• Clinicopathological and prognostic significance of metastasis-associated protein 1 expression and its correlation with angiogenesis in lung invasive adenocarcinomas, based on the 2011 IASLC/ATS/ERS classification

  2015cites this paper
• Epigenetics in lung cancer diagnosis and therapy

  2015cites this paper
• Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience

  2015cites this paper
• Molecular understanding of lung cancers-A review.

  2014cites this paper
• Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice

  2014cites this paper
• Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

  2014cites this paper
• Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India

  2014cites this paper
• The annoying pulmonary nodule on CT

  2014cites this paper
• Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients.

  2014cites this paper
• microRNAs: Significance for Sensitivity/Resistance of Lung Cancer Cells to Treatment

  2013cites this paper
• New Advances in the Precision Medicine of Lung Cancer

  2013cites this paper
• Prognosis in Patients With Symptomatic Metastatic Spinal Cord Compression: Survival in Different Cancer Diagnosis in a Cohort of 2321 Patients

  2013cites this paper
• Ursolic acid inhibits epithelial–mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells

  2013cites this paper
• Surgical Pathology of Lung Cancer

  2013cites this paper
• Diagnostic Techniques and Tissue Processing in Surgical Pathology

  2013cites this paper
• 肺癌的个体化靶向治疗

  2013cites this paper
• Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents.

  2013cites this paper
• Interobserver agreement and assay reproducibility of folate receptor α expression in lung adenocarcinoma: a prognostic marker and potential therapeutic target.

  2013cites this paper
• Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC)

  2013cites this paper
• Data set for reporting of lung carcinomas: recommendations from International Collaboration on Cancer Reporting.

  2013cites this paper
• EGFR and TTF-1 Gene Amplification in Surgically Resected Lung Adenocarcinomas: Clinicopathologic Significance and Effect on Response to EGFR-Tyrosine Kinase Inhibitors in Recurred Cases

  2013cites this paper
• CD24+/CD38- as new prognostic marker for non-small cell lung cancer

  2013cites this paper
• Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group

  2013cites this paper
• Digoxin Downregulates NDRG1 and VEGF through the Inhibition of HIF-1α under Hypoxic Conditions in Human Lung Adenocarcinoma A549 Cells

  2013cites this paper
• Clinical testing for molecular targets for personalized treatment in lung cancer

  2013cites this paper
• Targeted agents in second-line bladder cancer therapy

  2012cites this paper
• Impact of HER2 and PTEN simultaneous deregulation in non-small cell lung carcinoma: correlation with biological behavior.

  2012cites this paper
• Precision medicine for lung cancer: role of the surgical pathologist.

  2012cites this paper
• Lung cancer genotype-based therapy and predictive biomarkers: present and future.

  2012cites this paper
• MUTATIONS IN LUNG CANCER WITH CLINICAL SIGNIFICANCE

  2012cites this paper
• Personalized Targeted Therapy for Lung Cancer

  2012cites this paper
• LUNG CANCER AND GENDER DIFFERENCES

  2012cites this paper
• Genetic testing for respiratory disease: are we there yet?

  2012cites this paper